Insider Trading Activity Mirati Therapeutics, Inc. (NASDAQ:MRTX) – Major Shareholder Bought 286,163 shares of Stock

61

Insider Trading Activity For Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Boxer Capital, Llc , Major Shareholder of Mirati Therapeutics, Inc. (NASDAQ:MRTX) reportedly Bought 286,163 shares of the company’s stock at an average price of 5.6 for a total transaction amount of $1,602,512.80 SEC Form

Insider Trading History For Mirati Therapeutics, Inc. (NASDAQ:MRTX)

  • On 10/29/2013 Orbimed Advisors Llc, Major Shareholder Buy, 125,000 $17.50 with an average share price of $2,187,500.00 View SEC Filing   10/24/2013 per share and the total transaction amounting to Tang Capital Partners Lp.
  • On 7/1/2014 Orbimed Advisors Llc, Major Shareholder Sell, 107,332 $21.66 with an average share price of $2,324,811.12 View SEC Filing   11/26/2013 per share and the total transaction amounting to Charles M Baum.
  • On 2/3/2015 Orbimed Advisors Llc, Major Shareholder Buy, 100,000 $20.00 with an average share price of $2,000,000.00 View SEC Filing   1/29/2015 per share and the total transaction amounting to Bros. Advisors Lp Baker.
  • On 3/5/2015 Jamie Christensen, SVP Sell, 6,000 $25.41 with an average share price of $152,460.00 View SEC Filing   2/19/2015 per share and the total transaction amounting to Jamie Christensen.
  • On 9/16/2015 Bros. Advisors Lp Baker, Major Shareholder Buy, 150,000 $45.00 with an average share price of $6,750,000.00 View SEC Filing   5/26/2015 per share and the total transaction amounting to Jamie Christensen.
  • On 3/18/2016 Ltd. Braslyn, Major Shareholder Buy, 1,166 $19.34 with an average share price of $22,550.44 View SEC Filing   1/15/2016 per share and the total transaction amounting to Mark J. Gergen.
  • On 5/6/2016 Ltd. Braslyn, Major Shareholder Buy, 65,782 $18.21 with an average share price of $1,197,890.22 View SEC Filing   3/28/2016 per share and the total transaction amounting to Ltd. Braslyn.
  • Analyst Ratings For Mirati Therapeutics, Inc. (NASDAQ:MRTX)
    These are 4 Hold Ratings, 5 Buy RatingsThe current consensus rating for Mirati Therapeutics, Inc. (NASDAQ:MRTX) is Buy (Score: 2.56) with a consensus target price of $16.11 , a potential (195.62% upside)

    Analyst Ratings History For Mirati Therapeutics, Inc. (NASDAQ:MRTX)

    • On 6/1/2015 Brean Capital Downgraded rating Buy to Hold
    • On 3/1/2016 SunTrust Banks, Inc. Initiated Coverage of rating Buy with a price target of $32.00
    • On 6/6/2016 Citigroup Inc. Lower Price Target of rating Buy with a price target of $30.00 to $23.00
    • On 6/6/2016 Barclays PLC Lower Price Target of rating Overweight with a price target of $41.00 to $27.00
    • On 8/18/2016 Piper Jaffray Companies Set Price Target of rating Hold with a price target of $7.00
    • On 11/4/2016 Wedbush Reiterated Rating Outperform with a price target of $12.00
    • On 11/11/2016 Leerink Swann Reiterated Rating Hold with a price target of $7.00

    Recent Trading Activity for Mirati Therapeutics, Inc. (NASDAQ:MRTX)
    Shares of Mirati Therapeutics, Inc. closed the previous trading session at 5.45 down -0.10 -1.80% with 210,558 shares trading hands.

    An ad to help with our costs